EA200970447A1 - Соединения и композиции в качестве ингибиторов протеинкиназы - Google Patents
Соединения и композиции в качестве ингибиторов протеинкиназыInfo
- Publication number
- EA200970447A1 EA200970447A1 EA200970447A EA200970447A EA200970447A1 EA 200970447 A1 EA200970447 A1 EA 200970447A1 EA 200970447 A EA200970447 A EA 200970447A EA 200970447 A EA200970447 A EA 200970447A EA 200970447 A1 EA200970447 A1 EA 200970447A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- compositions
- proteinkinase inhibitors
- proteinkinase
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Изобретение обеспечивает новый класс соединений, фармацевтических композиций, включающих такие соединения, и способов применения таких соединений для лечения или предупреждения заболеваний или расстройств, связанных с аномальной или нерегулируемой киназной активностью, в частности, заболеваний или расстройств, которые включают аномальную активацию c-kit, PDGFRα и PDGFRβ киназ. Формула (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86437806P | 2006-11-03 | 2006-11-03 | |
PCT/US2007/083543 WO2008058037A1 (en) | 2006-11-03 | 2007-11-02 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200970447A1 true EA200970447A1 (ru) | 2009-10-30 |
Family
ID=39119736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970447A EA200970447A1 (ru) | 2006-11-03 | 2007-11-02 | Соединения и композиции в качестве ингибиторов протеинкиназы |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100048539A1 (ru) |
EP (1) | EP2079729A1 (ru) |
JP (1) | JP2010509349A (ru) |
KR (2) | KR20120049397A (ru) |
CN (1) | CN101622244A (ru) |
AU (1) | AU2007317349B2 (ru) |
BR (1) | BRPI0718677A2 (ru) |
CA (1) | CA2668190A1 (ru) |
CO (1) | CO6241115A2 (ru) |
CR (1) | CR10755A (ru) |
EA (1) | EA200970447A1 (ru) |
EC (1) | ECSP099378A (ru) |
IL (1) | IL198315A0 (ru) |
MA (1) | MA30906B1 (ru) |
MX (1) | MX2009004716A (ru) |
NO (1) | NO20092138L (ru) |
RU (1) | RU2009120882A (ru) |
SM (1) | SMAP200900031A (ru) |
TN (1) | TN2009000163A1 (ru) |
WO (1) | WO2008058037A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006027795A1 (en) | 2004-09-09 | 2006-03-16 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
EP2035369B1 (en) | 2006-07-05 | 2014-06-25 | Fibrotech Therapeutics PTY LTD | Therapeutic compounds |
CA2686382C (en) * | 2007-05-04 | 2013-09-17 | Irm Llc | Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors |
EP2152079A4 (en) * | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CA2697081C (en) | 2007-08-22 | 2013-04-23 | Irm Llc | 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors |
KR101171488B1 (ko) | 2007-08-22 | 2012-08-07 | 아이알엠 엘엘씨 | 키나제 억제제로서의 2-헤테로아릴아미노-피리미딘 유도체 |
CA2732789A1 (en) * | 2008-08-13 | 2010-02-18 | Novartis Ag | Treatment of pulmonary arterial hypertension |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
RU2011140404A (ru) * | 2009-03-06 | 2013-04-20 | Новартис Аг | Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak) |
IN2012DN03312A (ru) * | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
CA3034600C (en) * | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
NZ604018A (en) * | 2010-06-07 | 2015-02-27 | Novomedix Llc | Furanyl compounds and the use thereof |
US20130324530A1 (en) * | 2010-11-17 | 2013-12-05 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
CA2845169C (en) * | 2011-09-01 | 2022-04-19 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
KR20140071383A (ko) * | 2011-09-01 | 2014-06-11 | 아이알엠 엘엘씨 | C-kit 키나제 억제제로서의 화합물 및 조성물 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
US10435364B2 (en) * | 2013-04-17 | 2019-10-08 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
CN103288804A (zh) * | 2013-05-24 | 2013-09-11 | 苏州明锐医药科技有限公司 | 一种尼洛替尼的制备方法 |
CA2914620C (en) | 2013-06-05 | 2021-06-15 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
WO2015085229A1 (en) * | 2013-12-08 | 2015-06-11 | Van Andel Research Institute | Autophagy inhibitors |
HUE060660T2 (hu) | 2014-03-07 | 2023-04-28 | Biocryst Pharm Inc | Szubsztituált pirazolok mint humán plazma kallikrein-gátlók |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
CN106187995A (zh) * | 2015-05-05 | 2016-12-07 | 天津国际生物医药联合研究院 | 含酰胺键杂环类化合物及其制备方法和应用 |
US9661853B2 (en) * | 2015-09-04 | 2017-05-30 | Dow Agrosciences Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
WO2017053886A2 (en) * | 2015-09-23 | 2017-03-30 | Minerva Biotechnologies Corporation | Method of screening for agents for differentiating stem cells |
PL3426244T3 (pl) * | 2016-03-09 | 2023-09-25 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
SI3426243T1 (sl) | 2016-03-09 | 2021-11-30 | Raze Therapeutics, Inc. | Zaviralci 3-fosfoglicerat dehidrogenaze in uporabe le-teh |
CN105974131B (zh) * | 2016-06-16 | 2017-12-26 | 武汉大学 | c‑Kit作为药物成瘾治疗靶点的应用 |
CA3047125A1 (en) * | 2016-12-15 | 2018-06-21 | The Regents Of The University Of California | Compositions and methods for treating cancer |
JP7185631B2 (ja) | 2017-02-03 | 2022-12-07 | サータ セラピューティクス プロプライエタリー リミテッド | 抗線維化化合物 |
JP6994715B2 (ja) * | 2017-10-04 | 2022-02-04 | 国立大学法人京都大学 | Bcr-Ablタンパク質イメージング用分子プローブ |
CN108187052B (zh) * | 2018-02-05 | 2021-06-08 | 苏州大学 | Akt抑制剂在制备治疗血小板数量减少相关疾病药物中的用途 |
WO2022016021A1 (en) | 2020-07-15 | 2022-01-20 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
TW202237097A (zh) | 2020-11-19 | 2022-10-01 | 美商第三諧波生物公司 | 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法 |
CN113797345B (zh) * | 2021-10-22 | 2023-05-16 | 北京大学人民医院 | 糖皮质激素与糖酵解调节剂在制备急性移植物抗宿主病的药物中的应用 |
WO2023212612A2 (en) * | 2022-04-27 | 2023-11-02 | Qian Shawn | Certain chemical entities, compositions, and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002342878A1 (en) * | 2001-05-16 | 2002-11-25 | Axxima Pharmaceuticals Ag | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
WO2006027795A1 (en) * | 2004-09-09 | 2006-03-16 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
EP2942349A1 (en) * | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
US20090312349A1 (en) * | 2004-12-23 | 2009-12-17 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
-
2007
- 2007-11-02 RU RU2009120882/04A patent/RU2009120882A/ru not_active Application Discontinuation
- 2007-11-02 BR BRPI0718677-0A patent/BRPI0718677A2/pt not_active IP Right Cessation
- 2007-11-02 US US12/513,498 patent/US20100048539A1/en not_active Abandoned
- 2007-11-02 WO PCT/US2007/083543 patent/WO2008058037A1/en active Application Filing
- 2007-11-02 EP EP07844851A patent/EP2079729A1/en not_active Withdrawn
- 2007-11-02 CN CN200780049160A patent/CN101622244A/zh active Pending
- 2007-11-02 EA EA200970447A patent/EA200970447A1/ru unknown
- 2007-11-02 CA CA002668190A patent/CA2668190A1/en not_active Abandoned
- 2007-11-02 JP JP2009536405A patent/JP2010509349A/ja not_active Ceased
- 2007-11-02 KR KR1020127008731A patent/KR20120049397A/ko not_active Application Discontinuation
- 2007-11-02 AU AU2007317349A patent/AU2007317349B2/en not_active Expired - Fee Related
- 2007-11-02 KR KR1020097011383A patent/KR20090075889A/ko not_active Application Discontinuation
- 2007-11-02 MX MX2009004716A patent/MX2009004716A/es not_active Application Discontinuation
-
2009
- 2009-04-23 IL IL198315A patent/IL198315A0/en unknown
- 2009-04-29 CR CR10755A patent/CR10755A/es not_active Application Discontinuation
- 2009-04-29 TN TNP2009000163A patent/TN2009000163A1/fr unknown
- 2009-05-04 CO CO09044589A patent/CO6241115A2/es not_active Application Discontinuation
- 2009-05-04 SM SM200900031T patent/SMAP200900031A/it unknown
- 2009-05-18 MA MA31895A patent/MA30906B1/fr unknown
- 2009-06-02 EC EC2009009378A patent/ECSP099378A/es unknown
- 2009-06-02 NO NO20092138A patent/NO20092138L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2079729A1 (en) | 2009-07-22 |
NO20092138L (no) | 2009-07-13 |
ECSP099378A (es) | 2009-07-31 |
RU2009120882A (ru) | 2010-12-10 |
MA30906B1 (fr) | 2009-11-02 |
KR20090075889A (ko) | 2009-07-09 |
AU2007317349B2 (en) | 2011-10-20 |
KR20120049397A (ko) | 2012-05-16 |
TN2009000163A1 (en) | 2010-10-18 |
US20100048539A1 (en) | 2010-02-25 |
MX2009004716A (es) | 2009-07-17 |
AU2007317349A1 (en) | 2008-05-15 |
BRPI0718677A2 (pt) | 2013-11-26 |
CA2668190A1 (en) | 2008-05-15 |
WO2008058037A1 (en) | 2008-05-15 |
JP2010509349A (ja) | 2010-03-25 |
CN101622244A (zh) | 2010-01-06 |
CO6241115A2 (es) | 2011-01-20 |
SMAP200900031A (it) | 2009-07-14 |
IL198315A0 (en) | 2010-02-17 |
CR10755A (es) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
ATE544761T1 (de) | Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer | |
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MY167245A (en) | Compounds and compositions as c-kit kinase inhibitors | |
TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
GEP20135805B (en) | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS |